The purpose of this Funding Opportunity Announcement (FOA) is to stimulate the development of new and innovative sustained/extended release drugs and drug delivery systems (DDS) that can achieve extended durations (months to years) of HIV prevention in at-risk individuals.
NIH/NIAID: 5R01AI120748-02; Marc Michael Baum (PI); 06/26/15 - 05/31/20
NIH/NIAID: 4R01AI073146-09; Victor J. Garcia-Martinez (PI); 01/05/02 - 07/31/17
NIH/NIAID: 5R01AI117740-03; Christopher J. Destache (PI); 02/04/16 - 01/31/18
NIH/NIAD; 1R01AI131430-01; Soumya Rahima Benhabbour (PI); 03/06/17 - 02/29/20
NIH/NIMH; 5R01MH106380-02; Sarit A. Golub (PI); 01/16/15 - 11/30/19
NIH/NIAID; 4R01AI073146-09: Victor J. Garcia-Martinez (PI); 05/01/07 - 07/31/17
NIH/NIAID; 5UM1AI120184-02; Thomas Hope (PI); 07/07/15 - 06/30/20
The Gates Foundation invests in areas that advance the development and delivery of new HIV prevention methods while improving the efficiency and effectiveness of existing prevention and treatment efforts.